Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOBSTER neoadjuvant capivasertib plus SERD versus SERD alone in high-risk lobular breast cancer
2023-509292-17-00Phase 2Authorised
- Sponsor
- GBG Forschungs
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capivasertib, fulvestrant and camizestrant in Invasive Lobular Carcinoma (ILC) (2 arms), sponsored by GBG Forschungs. Primary endpoint: Complete cell cycle arrest. Planned start Nov 2024; status: authorised.
02
Drugs
capivasertibfulvestrantcamizestrant
03
Conditions
Invasive Lobular Carcinoma (ILC)
Beyond the preview
Go deeper on 2023-509292-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509292-17-00.